Lagnese Meena, Daar Eric S
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, David Geffen School of Medicine at UCLA, Division of HIV Medicine and Infectious Diseases, 1124 W Carson Street, N-24, Torrance, CA 90502, USA.
Expert Opin Pharmacother. 2008 Apr;9(5):687-700. doi: 10.1517/14656566.9.5.687.
A significant number of treatment-experienced patients with HIV-1 infection develop drug-resistant virus.
To define strategies for managing the antiretroviral-experienced patient and summarize current data with commonly used drugs for this population.
This review incorporated data from most recent antiretroviral treatment guidelines, published papers on related topics, and peer-reviewed publications or presentations at research meetings on the safety and efficacy of agents commonly used in this patient population.
RESULTS/CONCLUSION: The patient experiencing virologic failure on treatment must be evaluated for their ability to adhere with therapy and to define the number of available active drugs. A viable regimen should include at least two fully active agents, with the goal being to achieve complete virologic suppression.
大量有过治疗经历的HIV-1感染患者会产生耐药病毒。
确定管理有抗逆转录病毒治疗经历患者的策略，并总结针对该人群常用药物的当前数据。
本综述纳入了最新抗逆转录病毒治疗指南中的数据、相关主题的已发表论文，以及关于该患者人群常用药物安全性和有效性的同行评审出版物或研究会议上的报告。
结果/结论：必须评估治疗中出现病毒学失败的患者坚持治疗的能力，并确定可用的活性药物数量。一个可行的治疗方案应至少包括两种完全有效的药物，目标是实现完全的病毒学抑制。
